Koray Demirtas, MD 1 I read the article entitled "Evaluation of the Predictive Value of CHA 2 DS 2 -VASc score for In-Stent Restenosis" by Yilmaz et al 1 with great interest. They reported that the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age 75 years, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65-74 years, female gender) score could be used as a predictor of in-stent restenosis (ISR) in patients who underwent percutaneous coronary intervention (PCI) due to stable coronary artery disease.
1 They also found a significant positive correlation between CHA 2 DS 2 -VASc score and C-reactive protein levels (r ¼ .384, P < .001).
Although interventional approaches and pharmacological therapies have improved, ISR remains a major problem. It was previously reported that ISR could result from several mechanisms including inflammation and oxidative stress. 2 Many easily available inflammatory and oxidative biomarkers including serum bilirubin, uric acid, albumin, and vitamin D as well as monocyte to high-density lipoprotein cholesterol ratio and resting heart rate may be independent risk factors for atherosclerosis, ISR, and cardiovascular events. [3] [4] [5] [6] [7] [8] [9] In the study by Yilmaz et al, 1 there are no data regarding these biochemical parameters. In addition, Kocas et al suggested that statin nonadherence in patients with PCI was associated with an increased risk of ISR. 10 However, Yilmaz et al 1 did not report the rates of statin usage in their study population. Combined information regarding multiple inflammatory biomarkers could be useful to evaluate the risk of ISR in patients who underwent PCI.
